DPT 2: Exam 5 (Case Studies)

POPADAD

-Aspirin 100 mg vs. Placebo

-Aspirin did not reduce MACE in asymptomatic PAD

patients with DM

AAA

-Aspirin 100 mg vs. Placebo

-Aspirin did not reduce MACE in asymptomatic PAD

patients

ATC

-Various antiplatelets vs. Placebo

-Antiplatelet agents compared with placebo reduced MACE in symptomatic PAD patients

CLIPS

-Aspirin 100 mg vs. Placebo/antioxidant

-Aspirin reduced MACE/leg ischemia in mild-moderate PAD without increasing bleed risk

CAPRIE

-Clopidogrel 75 mg vs. aspirin 325 mg

-Clopidogrel is more effective than aspirin in reducing

MACE in symptomatic PAD

EUCLID

-Ticagrelor 90 mg BID vs. clopidogrel 75 mg

-Ticagrelor is NOT superior to clopidogrel in reducing

MACE or limb events, with similar rates of bleeding

CHARISMA

-Clopidogrel 75 mg + ASA vs. ASA

-Statistically nonsignificant decrease in MACE and limb events in clopidogrel + ASA, with higher risk of minor bleeding

PLATO

-Ticagrelor 90 mg BID + ASA vs. clopidogrel 75 mg + ASA

-Statistically nonsignificant decrease in MACE in ticagrelor

+ ASA vs. clopidogrel vs. ASA in ACS with PAD

PEGASUS-TIMI

-Ticagrelor 90/60 mg BID + ASA vs. ASA

-Ticagrelor + ASA reduced MACE and MALE events compared with ASA alone in PAD patients with prior MI

WAVE

-Warfarin or acenocoumarol + antiplatelet vs. antiplatelet

-Anticoagulant + antiplatelet was not more effective than

antiplatelet alone, increased bleeding

COMPASS

-Rivaroxaban 2.5 mg BID + ASA or rivaraoxaban 5 mg BID vs. ASA

-Rivaroxaban + ASA reduced risk of MACE and MALE but increased

bleeding in patients with symptomatic PAD

VOYAGER

-Rivaroxaban 2.5 mg BID + ASA 100 mg vs. ASA 100 mg

-Statistically significant decrease in composite events (carried by ALI) vs. ASA alone, nonstatistically significant increase in fatal bleeding